Pilot Read this carefully
It is less effective in other subtypes of CD20-positive lymphoma and for retreatment, even with CD20 still expressed. Thus, binding of rituximab to CD20 is not sufficient to kill many lymphoma cells, indicating that there are mechanisms of resistance.
rituximab doesn't stick to many cancers, FVRL's drug could stick now with the new crazy glue someone invented. So now all that $140 million dollars worth of FVRL test data they thought was junk because their drug woudln't stick to the Cancer cells has to be looked at again in light of now it could stick because of the new crazy glue someone invented. That's why this stock could go to many, many dollars by taking over a big chunk of rituximabs $5.6 billion in sales and is why the China drug guys want in.
Best Success to ALL MMRF'S Shareholders!
